Maria Joäo Brito

Dr. Maria Joäo Brito

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in International Journal of Pediatric Otorhinolaryngology
Verified
Journal Article
Closed access
CGCatarina Garcia
Catarina Garcia
ASAna Bárbara Salgueiro
Ana Bárbara Salgueiro
CLCatarina Luís
Catarina Luís
PCPaula Correia
Paula Correia
MBMaria Joäo Brito
Maria Joäo Brito

1 June 2014 in Gene
Verified
Journal Article
Closed access
JSJoana A. Santos
Joana A. Santos
JAJuan I. Aróstegui
Juan I. Aróstegui
MBMaria Joäo Brito
Maria Joäo Brito
CNConceição Neves
Conceição Neves
MCMarta Conde
Marta Conde

RARosa Amorim-Figueiredo
Rosa Amorim-Figueiredo
ALAna Pereira Lemos
Ana Pereira Lemos
TRTiago Rito
Tiago Rito
MCMarta Conde
Marta Conde
MBMaria Joäo Brito
Maria Joäo Brito
FPFátima Pinto
Fátima Pinto
Background: Kawasaki disease (KD) is a type of vasculitis in which giant coronary artery aneurysms (CAAs) can occur. There are no specific guidelines for managing giant CAAs that develop quickly and are at risk of rupture. Regarding cardiovascular drugs, only beta-blockers are formally recommended in the acute phase of KD. Case presentation: A 6-month-old male patient with multiresistant Kawasaki disease and giant CAAs that continued to enlarge after controlling systemic inflammation was examined. The patient required three doses of intravenous immunoglobulin, methylprednisolone pulses, and anakinra and infliximab to normalize systemic inflammation. Due to the rapid increment of aneurysms’ dimensions and the risk of rupture, we introduced anticoagulant therapy and propranolol plus captopril, and titration doses were introduced according to a tolerated decrease in heart rate and arterial pressure. CAAs increment stabilized and slowly reduced their dimensions. Conclusions: The authors describe an atypical case of multiresistant KD with giant rapidly increasing CAAs even after controlling systemic inflammation. The introduction of a beta-blocker and an angiotensin-converting enzyme (ACE) inhibitor was demonstrated to be useful for stabilizing giant CAAs growth and reducing the potential risk of rupture.

25 November 2011
Verified
Journal Article
Closed access
MCMarta Cabral
Marta Cabral
PCPaula Correia
Paula Correia
MBMaria Joäo Brito
Maria Joäo Brito
MCMarta Conde
Marta Conde
HCHelena Carreiro
Helena Carreiro

18 February 2014
Verified
Book Chapter
Closed access
PDF file
MNManuel Cassiano Neves
Manuel Cassiano Neves
CGCatarina Gouveia
Catarina Gouveia
MBMaria Joäo Brito
Maria Joäo Brito
MMMaria Favila Menezes
Maria Favila Menezes
PFPedro Falcão
Pedro Falcão

22 August 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
CMCatarina Gregório Martins
Catarina Gregório Martins
MÂMiguel Ângelo Simão Ângelo-Dias
Miguel Ângelo Simão Ângelo-Dias
MCMaria Jesus de Jesus Fernandes Chasqueira
Maria Jesus de Jesus Fernandes Chasqueira
MBMaria Joäo Brito
Maria Joäo Brito
TSTiago Milheiro Silva
Tiago Milheiro Silva
PPPaulo Paixão
Paulo Paixão
Children with COVID-19 typically experience milder symptoms and lower hospitalization rates, though severe cases do occur. Understanding age-related immune responses is crucial for future preparedness. We characterized immune response dynamics to SARS-CoV-2 in 145 samples from 119 pediatric patients (<18 years) with confirmed infection, assessed at four distinct time points: <14 days, 14 days–3 months, 3–6 months, and 6–12 months post-infection. At infection, patients presented increased activated T-cells, higher levels of exhaustion (i.e., PD-1+), lower numbers of unswitched memory B-cells, and increased antibody-secreting cells (ASCs). Both humoral and cellular anti-SARS-CoV-2 responses increased over time (all patients showed measurable responses in the last assessment). Asymptomatic/mildly symptomatic patients (58.6%) showed increased specific cellular responses from infection onwards, along with enriched memory B-cell subsets (but not ASCs), and distinct T-cell activation profiles. Children with severe disease were younger, predominantly boys, displayed altered T/B-cell ratios, and reduced PHA responses when infected. Compared to adolescents, younger children showed lower antibody titers and weaker cellular responses to SARS-CoV-2, possibly underlining the higher prevalence of severe manifestations in younger children. Our study illustrates important age-, gender-, and disease severity-dependent variations in immune responses to SARS-CoV-2, which can be helpful in improving patient management and immunization strategies adjusted to age groups.